Original articleThe angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice
Introduction
Atherosclerosis is one of the chronic inflammatory diseases [1]. Many factors cause atherosclerosis, where the renin-angiotensin system (RAS) plays critical roles in the pathogenesis of atherosclerosis by promoting a series of coordinated cellular and molecular events observed in lesions [2], [3]. Recent clinical trials suggest that pharmacological blockade of RAS with Angiotensin II type 1 receptor (AT1R) blockers (ARBs) is effective in the treatment of patients with cardiovascular diseases [4]. These drugs exert various favorable effects on endothelial function [5], [6], cardiac function [7], [8], cerebral vascular function [9], [10] and renal function [11] by inhibiting RAS other than blood pressure lowering effect. Accumulating evidence suggests the interaction between RAS and metabolic systems [12], [13]. Actually, several studies demonstrated that AT1R blockade has additional therapeutic benefits in the metabolic syndrome and other obesity-related disorders beyond blood pressure lowering effect [14], [15].
Recent reports suggest that telmisartan, an ARB, functions as a partial agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), leading to improvement of glucose and lipid profiles in vivo and in vitro [16], [17], [18]. Benson et al. reported that none of the other commercially available angiotensin II receptor antagonists appeared to activate PPAR-γ when tested at concentrations typically achieved in plasma with conventional oral dosing [16]. PPAR-γ agonist, including pioglitazone and rosiglitazone, improve insulin resistance [19]. Furthermore, accumulating evidence suggests that activators of PPAR-γ exert anti-inflammatory, anti-oxidative and anti-proliferative effects on vascular wall cells, thus decreasing the risks for atherosclerosis [20]. Telmisartan is hoped to have the potential to treat both hemodynamic and biochemical features in patients with metabolic syndromes and to provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations by simultaneously blocking the angiotensin II receptor and activating PPAR-γ [16], [21].
Here, we investigated the additional effects of telmisartan that is not related to AT1R blockade by administrating telmisartan to AT1aR deficient hypercholesterolemic mice. Administration of telmisartan prevented the development of atherosclerosis even in AT1aR deficient animals. Telmisartan also improved metabolic parameters including body weight, serum high-density lipoprotein (HDL) levels, and blood pressure in these mice. Telmisartan has atheroptoective effects that are not related to the RAS.
Section snippets
Animals and drug administration
ApoE−/− mice (C57BL/6J background) were originally purchased from Jackson Laboratory. AT1aR knockout (AT1R−/−) mice (C57BL/6J background) were previously described [3]. We generated double knockout mice deficient of ApoE and AT1aR by cross-breeding ApoE−/− mice and AT1aR−/− mice. All procedures involving experimental animals were performed in accordance with protocols approved by the institutional committee for animal research of The University of Tokyo and complied with the Guide for the Care
Effects of telmisartan on atherosclerotic plaque formation in ApoE−/− mice
We compared atherosclerotic lesion progression between male ApoE−/−AT1aR+/+ mice (n = 4) and ApoE−/−AT1aR−/− mice (n = 4) fed normal chow at 24-weeks of age. Result of en face Sudan IV staining demonstrated that genetic AT1aR disruption significantly reduced development of atherosclerosis in ApoE−/− mice (Sudan IV-positive area: 20.8 ± 3.6% versus 10.7 ± 1.9%, P < 0.05, Fig. 1A). Next, 10 mg/kg/day telmisartan (n = 4) or 30 mg/kg/day hydralazine (n = 3) was administered to six-week-old male ApoE−/− mice fed a
Discussion
In this study, the result of genetic ablation of AT1aR in ApoE−/− mice demonstrated that AT1aR plays critical roles in atherogenesis in hypercholesterolemic animals. We also demonstrated that telmisartan reduces development of atherosclerosis and increases stability of plaques not only in ApoE−/− mice but also in ApoE−/−AT1aR−/− mice, which have no AT1aR genetically. Telmisartan is a unique ARB with selective PPARγ-activating activity. Our findings suggest that telmisartan could exert
Conflict of interest statement
None.
Sources of funding
This study was supported in part by the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry and by grants from the Ministry of Education, Culture, Sports, Science and Technology (Knowledge Cluster and Scientific Research on Innovative Areas) and the Ministry of Health, Labor and Welfare of Japan.
References (32)
- et al.
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study ELITE)
Lancet
(1997) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials
Diabetes Metab
(2004)- et al.
The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?
Int J Biochem Cell Biol
(2003) - et al.
An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
FEBS Lett
(2004) - et al.
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
J Biol Chem
(1998) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
Pharmacol Ther
(2006)- et al.
PPARgamma in endothelial cells influences high fat diet-induced hypertension
Am J Hypertens
(2005) - et al.
Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect
Am J Hypertens
(2006) Atherosclerosis – an inflammatory disease
N Engl J Med
(1999)Theodore cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis
Hypertension
(2001)